» Articles » PMID: 18849013

Lifetime and Treatment-phase Costs Associated with Colorectal Cancer: Evidence from SEER-Medicare Data

Overview
Specialty Gastroenterology
Date 2008 Oct 14
PMID 18849013
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: This study provides detailed estimates of lifetime and phase-specific colorectal cancer (CRC) treatment costs.

Methods: This retrospective cohort study included patients aged 66 years and older, newly diagnosed with CRC in a Surveillance Epidemiology and End Results (SEER) registry (1996-2002), matched 1:1 (by age, sex, and geographic region) to patients without cancer from a 5% sample of Medicare beneficiaries. The Kaplan-Meier sample average estimator was used to estimate observed 10-year costs, which then were extrapolated to 25 years. A secondary analysis computed costs on a per-survival-year basis to adjust for differences in mortality by stage and age. Costs were expressed in 2006 US$, with future costs discounted 3% per year.

Results: Our sample included 56,838 CRC patients (41,256 colon cancer [CC] patients and 15,582 rectal cancer [RC] patients; mean +/- SD age, 77.7 +/- 7.1 y; 55% women; and 86% white). Lifetime excess costs were $29,500 for CC and $26,500 for RC patients. Per survival year, stage IV CRC patients incurred $31,000 in excess costs compared with $3000 for stage 0 patients. CRC patients incurred excess costs of $33,500 in the initial phase, $4500/y in the continuing phase, and $14,500 in the terminal phase. RC patients had lower costs than CC patients in the initial phase, but higher costs in both the continuing and terminal phases.

Conclusions: Excess costs associated with CRC are striking and vary considerably by treatment phase, cancer subsite, and stage at diagnosis. Interventions aimed at earlier diagnosis and prevention have the potential to reduce cancer-related health care costs.

Citing Articles

Phase-Based and Lifetime Health System Costs of Care for Patients Diagnosed with Leukemia and Lymphoma: A Population-Based Descriptive Study.

Agarwal A, Kekre N, Atkins H, Imsirovic H, Hutton B, Coyle D Curr Oncol. 2024; 31(8):4192-4208.

PMID: 39195296 PMC: 11352321. DOI: 10.3390/curroncol31080313.


Medical costs of Swedish nursing home residents at the end of life: a retrospective observational registry study.

Salaj D, Schultz T, Strang P BMC Geriatr. 2024; 24(1):580.

PMID: 38965491 PMC: 11225223. DOI: 10.1186/s12877-024-05043-9.


Estimation of the Three Phases by Direct Cost of Care for Non-surviving Patients with Cancer: A National Population-based Patient-level Study.

Youk T, Hong J, Park B, Park Y, Park E J Cancer. 2024; 15(1):20-29.

PMID: 38164281 PMC: 10751664. DOI: 10.7150/jca.78491.


Cost-Effectiveness of Liquid Biopsy for Colorectal Cancer Screening in Patients Who Are Unscreened.

Aziz Z, Wagner S, Agyekum A, Pumpalova Y, Prest M, Lim F JAMA Netw Open. 2023; 6(11):e2343392.

PMID: 37971743 PMC: 10654798. DOI: 10.1001/jamanetworkopen.2023.43392.


Economic Burden of Cancer for the First Five Years after Cancer Diagnosis in Patients with Human Immunodeficiency Virus in Korea.

Jang Y, Kim T, Kim B, Kim J, Seong H, Kim Y J Cancer Prev. 2023; 28(2):53-63.

PMID: 37434797 PMC: 10331032. DOI: 10.15430/JCP.2023.28.2.53.